BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)

TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of $193.3 million. In a statement by their CEO, Michael Weiss, 2025 marked a good year for TG Therapeutics, especially with the momentum and organization of BRIUMVI.

The company registered substantial year-over-year growth in the U.S. and globally, driven by increased adoption and availability, while also advancing its late-stage clinical programs and strengthening its financial foundation. As it begins 2026, it continues to build on this foundation with good financial guidance, several key clinical milestones ahead, and a disciplined approach to operating the business, thus enabling it to continue delivering value to patients, healthcare providers, and shareholders.

Back on February 2, a couple of weeks before the earnings results came out, JPMorgan analyst Brian Cheng reduced the firm’s price target on TG Therapeutics Inc. (NASDAQ:TGTX) to $46 from $49. The analyst maintained his Overweight rating on the stock, with a revised upside potential of more than 57%.

TG Therapeutics Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company dedicated to transforming the treatment landscape for B-cell mediated diseases. They specialize in acquiring, developing, and commercializing innovative therapies, such as BRIUMVI, to help patients manage autoimmune conditions such as multiple sclerosis. By precisely targeting B-cell disorders, they aim to improve patient outcomes and quality of life.

While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.